Floatz logo

Mesothelin-Directed Car-T Cells

Pancreatic Carcinoma

Essen BiotechCell therapyPhase 1/2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the Pancreatic Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Alliance for Clinical Trials in Oncology
Phase 2/3BB
Cyclophosphamide
Essen Biotech
Phase 2B
Veliparib
National Cancer Institute (NCI)
Phase 2B
Epirubicin
Seagen, a wholly owned subsidiary of Pfizer
Phase 2B
Pembrolizumab
Xencor, Inc.
Phase 2B

View all 49 →

Same molecule, other indications

Mesothelin-Directed Car-T Cells is also rated in:

Pancreatic Cancer Non-resectableDormant
CC
Indicative ·
47 / 100
View asset →
Pancreatic CancerDormant
CC
Indicative ·
40 / 100
View asset →
Solid Tumor, AdultDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →